Payment overview · 2025
General Payments
$1,414.82
10 reported records · 3 companies
Healthcare provider profile · identity verified
Sabrina Ann Benjamin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OLYMPIA, WA · NPI 1447280334
Verified facts
What the public records show
CMS Open Payments records show Sabrina Ann Benjamin, MD received $1,414.82 in general payments during 2025 across 10 reported records.
Novartis Pharmaceuticals Corporation accounted for 92.8% of that reported general-payment amount.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,312.35 | 92.8% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $70.27 | 5.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.20 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $949.28 | 3 |
| Food and Beverage | $465.54 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 53 |
| Gabapentin | Gabapentin | 227 | 32 |
| Furosemide | Furosemide | 221 | 22 |
| Jardiance | Empagliflozin | 221 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 199 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 158 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 141 | 13 |
| Lisinopril | Lisinopril | 131 | 20 |
| Baclofen | Baclofen | 126 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 18 |
| Xarelto | Rivaroxaban | 103 | 12 |
| Potassium Chloride | Potassium Chloride | 102 | 17 |
| Famotidine | Famotidine | 87 | 15 |
| Carvedilol | Carvedilol | 86 | 12 |
| Divalproex Sodium | Divalproex Sodium | 83 | 13 |
| Metformin Hcl | Metformin Hcl | 83 | 12 |
| Entresto | Sacubitril/Valsartan | 82 | suppressed |
| Olanzapine | Olanzapine | 81 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 16 |
| Trazodone Hcl | Trazodone Hcl | 72 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 12 |
| Eliquis | Apixaban | 66 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 65 | suppressed |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Lubiprostone | Lubiprostone | 57 | suppressed |
| Allopurinol | Allopurinol | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 19 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 13 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 38 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Losartan Potassium | Losartan Potassium | 36 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 29 | 11 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | suppressed |
| Humalog | Insulin Lispro | 23 | 11 |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Rytary | Carbidopa/Levodopa | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,414.82 · 10 records | Novartis Pharmaceuticals Corporation | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error